Cat. No.: DAB-0011765
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu262 of human AQP5 protein. Antibodies are purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | AQP5 |
| UniProt No. | P55064 |
| Gene ID | 362 |
| Gene Description | Aquaporin 5 is a plasma membrane water channel whose overexpression in human cancers, such as breast, pancreatic, and colon cancers, has been associated with poor prognosis and metastasis. In colorectal cancer cells, AQP5 has been shown to regulate migration and invasion, as well as expression of epithelial-mesenchymal transition factors. Knockdown of AQP5 inhibits the Wnt/β-Catenin pathway. Localization of AQP5 is altered in gastric cancer, and AQP5 is a marker for pyloric stem cells. In hepatocellular carcinoma, downregulation of AQP5 inhibits metastasis and EMT through inactivation of the NF-κB signaling pathway, and AQP5 is therefore a potential therapeutic target for HCC. Phosphorylation of AQP5 at Ser156, possibly by PKA, activates the Ras signaling pathway in NIH/3T3 cells. AQP5 alters cell shape and actin dynamics without inducing EMT in normal epithelial MDCK cells, and this effect likely requires phosphorylation of AQP5 at Ser156. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
